Understanding and targeting resistance mechanisms in NSCLC
J Rotow, TG Bivona - Nature Reviews Cancer, 2017 - nature.com
The expanding spectrum of both established and candidate oncogenic driver mutations
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
identified in non-small-cell lung cancer (NSCLC), coupled with the increasing number of …
MET-dependent solid tumours—molecular diagnosis and targeted therapy
Attempts to develop MET-targeted therapies have historically focused on MET-expressing
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …
cancers, with limited success. Thus, MET expression in the absence of a genomic marker of …
Polyclonal Secondary FGFR2 Mutations Drive Acquired Resistance to FGFR Inhibition in Patients with FGFR2 Fusion–Positive Cholangiocarcinoma
Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising
therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The …
therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The …
Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors in patients with MET exon 14–mutant NSCLC
Purpose: Molecular mechanisms of acquired resistance to MET tyrosine kinase inhibitors
(TKI) are poorly understood. We aimed to characterize the genomic mechanisms of …
(TKI) are poorly understood. We aimed to characterize the genomic mechanisms of …
Targeting MET Dysregulation in Cancer
Aberrant MET signaling can drive tumorigenesis in several cancer types through a variety of
molecular mechanisms including MET gene amplification, mutation, rearrangement, and …
molecular mechanisms including MET gene amplification, mutation, rearrangement, and …
Capmatinib (INC280) is active against models of non–small cell lung cancer and other cancer types with defined mechanisms of MET activation
Purpose: The selective MET inhibitor capmatinib is being investigated in multiple clinical
trials, both as a single agent and in combination. Here, we describe the preclinical data of …
trials, both as a single agent and in combination. Here, we describe the preclinical data of …
[HTML][HTML] Sensitivity and resistance of MET exon 14 mutations in lung cancer to eight MET tyrosine kinase inhibitors in vitro
T Fujino, Y Kobayashi, K Suda, T Koga… - Journal of Thoracic …, 2019 - Elsevier
Background MNNG HOS transforming gene (MET) exon 14 mutations in lung cancer,
including exon 14 skipping and point mutations, have been attracting the attention of …
including exon 14 skipping and point mutations, have been attracting the attention of …
[HTML][HTML] The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the why, the how, the who, the unknown, and the inevitable
T Reungwetwattana, Y Liang, V Zhu, SHI Ou - Lung cancer, 2017 - Elsevier
A number of small molecule tyrosine kinase inhibitors (TKIs) have now been approved for
the treatment of non-small cell lung cancers (NSCLC), including those targeted against …
the treatment of non-small cell lung cancers (NSCLC), including those targeted against …
Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress
JJ Cui - Journal of medicinal chemistry, 2014 - ACS Publications
The HGF/MET signaling pathway is critical in mediating a wide range of normal
physiological functions including embryological development, wound healing, and tissue …
physiological functions including embryological development, wound healing, and tissue …
[HTML][HTML] Acquired resistance to crizotinib in NSCLC with MET exon 14 skipping
Introduction MET proto-oncogene, receptor tyrosine kinase gene (MET) exon 14 skipping is
a targetable alteration in lung cancer. Treatment with MET proto-oncogene, receptor tyrosine …
a targetable alteration in lung cancer. Treatment with MET proto-oncogene, receptor tyrosine …